| Methods |
2‐ to 5‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 92‐109 mm Hg on 2 consecutive clinic visits during run‐in; 7‐week double‐blind treatment |
| Participants |
Captopril 12.5 mg TID: n=83(all males); mean age=55.7(9.8) years; baseline sitting SBP=147.8(14.6) mm Hg, DBP=97.0(3.6) mm Hg;
Captopril 25 mg TID: n=84(all males); mean age=55.7(8.1) years; baseline sitting SBP=147.4(11.9) mm Hg, DBP=97.9(3.7) mm Hg;
Captopril 37.5 mg BID: n=88(all males); mean age=54.9(7.9) years; baseline sitting SBP=149.0(13.1) mm Hg, DBP=97.5(4.7) mm Hg;
Captopril 50 mg TID: n=89(all males); mean age=55.1(8.0) years; baseline sitting SBP=148.2(16.0) mm Hg, DBP=98.1(4.7) mm Hg;
Placebo: n=83(all males); mean age=54.4(8.0) years; baseline sitting SBP=146.3(14.6) mm Hg, DBP=97.8(4.6) mm Hg |
| Interventions |
Captopril 12.5 mg three times daily,
Captopril 25 mg three times daily,
Captopril 37.5 mg twice daily,
Captopril 50 mg three times daily,
Placebo;
all patients were directed to take the capsules at least 1 h before breakfast, 2 h after lunch, and at bedtime, ie, at least 2 h after dinner |
| Outcomes |
Mean change from baseline in sitting SBP/DBP using mercury sphygmomanometer; WDAE; visits were scheduled approx 3 h from the time the patient took his last dose of medication |
| Notes |
BP change and SE of change reported; endpoint BP and SD reported; calculated SD of change from N and change SE; BP data from Table 4, p. 1953; Jadad score=4; funding source= E.R. Squibb & Sons Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
